The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Clopidogrel Teva Pharma clopidogrel | Teva Pharma B.V. | Ischemic Attack, Transient; Peripheral Vascular Diseases; Myocardial Infarction; Acute Coronary Syndrome | 🇪🇺 EU | Order → |
| Cokiera | AbbVie Limited | Hepatitis C, Chronic | 🇪🇺 EU | Order → |
| Combimarv insulin human | Marvel Life Sciences Ltd. | 🇪🇺 EU | Order → | |
| Comfyde carisbamate | Janssen-Cilag International NV | Epilepsy | 🇪🇺 EU | Order → |
| Contusugene Ladenovec Gendux | Gendux Molecular Limited | Head and Neck Neoplasms; Carcinoma, Squamous Cell | 🇪🇺 EU | Order → |
| Corluxin mifepristone Orphan | FGK Representative Service GmbH | Cushing Syndrome | 🇪🇺 EU | Order → |
| CureVac’s COVID-19 vaccine (CVnCoV) COVID-19 mRNA vaccine | CureVac AG | 🇪🇺 EU | Order → | |
| Cylatron peginterferon alfa-2b | SP Europe | Melanoma | 🇪🇺 EU | Order → |
| Dabigatran etexilate Teva dabigatran etexilate Generic | Teva GmbH | Venous Thromboembolism | 🇪🇺 EU | Order → |
| Datopotamab deruxtecan Daiichi Sankyo datopotamab deruxtecan | Daiichi Sankyo Europe GmbH | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU | Order → |
| Dazluma troriluzole | Biohaven Bioscience Ireland Limited | Spinocerebellar Ataxias | 🇪🇺 EU | Order → |
| Deqtynet copper (64Cu) oxodotreotide Orphan | CIS bio international | Radionuclide Imaging | 🇪🇺 EU 2026-05-21 | Order → |
| Desloratadine Krka desloratadine Generic | KRKA tovarna zdravil d.d. Novo mesto | Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal | 🇪🇺 EU | Order → |
| Dexamethasone Taw dexamethasone phosphate | Taw Pharma (Ireland) Ltd | COVID-19 virus infection; Brain Edema; Respiratory Distress Syndrome, Adult; Asthma; Skin Diseases; Autoimmune Diseases; Arthritis; Vomiting; Inflammation; Eye | 🇪🇺 EU | Order → |
| Dexxience betrixaban | Portola Pharma UK Limited | Venous Thromboembolism | 🇪🇺 EU 2018-07-26 | Order → |
| Dimherity dimethyl fumarate Generic | Sandoz GmbH | Multiple Sclerosis, Relapsing-Remitting | 🇪🇺 EU | Order → |
| Diractin ketoprofen | IDEA AG | Osteoarthritis | 🇪🇺 EU | Order → |
| Ditelos strontium ranelate;colecalciferol | Les Laboratoires Servier | 🇪🇺 EU | Order → | |
| Docetaxel Mylan docetaxel Generic | Mylan S.A.S. | Carcinoma, Non-Small-Cell Lung; Breast Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Adenocarcinoma; Prostatic Neoplasms | 🇪🇺 EU | Order → |
| Docetaxel SUN docetaxel Generic | Sun Pharmaceutical Industries Europe B.V. | Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Breast Neoplasms; Head and Neck Neoplasms | 🇪🇺 EU | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.